288 related articles for article (PubMed ID: 33424833)
1. Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.
Cross DL; Verheul MK; Leipold MD; Obermoser G; Jin C; Jones E; Starr JS; Mohorianu I; Blohmke CJ; Maecker HT; Napolitani G; Hill J; Pollard AJ
Front Immunol; 2020; 11():574057. PubMed ID: 33424833
[TBL] [Abstract][Full Text] [Related]
2. IgA and IgG1 Specific to Vi Polysaccharide of
Dahora LC; Jin C; Spreng RL; Feely F; Mathura R; Seaton KE; Zhang L; Hill J; Jones E; Alam SM; Dennison SM; Pollard AJ; Tomaras GD
Front Immunol; 2019; 10():2582. PubMed ID: 31781100
[TBL] [Abstract][Full Text] [Related]
3. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
[TBL] [Abstract][Full Text] [Related]
4. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
Qadri F; Khanam F; Liu X; Theiss-Nyland K; Biswas PK; Bhuiyan AI; Ahmmed F; Colin-Jones R; Smith N; Tonks S; Voysey M; Mujadidi YF; Mazur O; Rajib NH; Hossen MI; Ahmed SU; Khan A; Rahman N; Babu G; Greenland M; Kelly S; Ireen M; Islam K; O'Reilly P; Scherrer KS; Pitzer VE; Neuzil KM; Zaman K; Pollard AJ; Clemens JD
Lancet; 2021 Aug; 398(10301):675-684. PubMed ID: 34384540
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
Jin C; Gibani MM; Moore M; Juel HB; Jones E; Meiring J; Harris V; Gardner J; Nebykova A; Kerridge SA; Hill J; Thomaides-Brears H; Blohmke CJ; Yu LM; Angus B; Pollard AJ
Lancet; 2017 Dec; 390(10111):2472-2480. PubMed ID: 28965718
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
[TBL] [Abstract][Full Text] [Related]
7. Specific and Cross-reactive Plasmablast Response in Humans after Primary and Secondary Immunization with Vi Capsular Polysaccharide Typhoid Vaccine.
Pakkanen SH; Kantele JM; Rombo L; Kantele A
Scand J Immunol; 2017 Oct; 86(4):207-215. PubMed ID: 28675263
[TBL] [Abstract][Full Text] [Related]
8. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.
Wahid R; Pasetti MF; Maciel M; Simon JK; Tacket CO; Levine MM; Sztein MB
Clin Immunol; 2011 Feb; 138(2):187-200. PubMed ID: 21146460
[TBL] [Abstract][Full Text] [Related]
9. Transcutaneous Vaccination with Conjugate Typhoid Vaccine Vi-DT Induces Systemic, Mucosal, and Memory Anti-Polysaccharide Responses.
Bhuiyan MS; Kalsy A; Arifuzzaman M; Charles RC; Harris JB; Calderwood SB; Qadri F; Ryan ET
Am J Trop Med Hyg; 2020 Sep; 103(3):1032-1038. PubMed ID: 32720632
[TBL] [Abstract][Full Text] [Related]
10. Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV).
Voysey M; Pollard AJ
Clin Infect Dis; 2018 Jun; 67(1):18-24. PubMed ID: 29351594
[TBL] [Abstract][Full Text] [Related]
11. Vi-specific serological correlates of protection for typhoid fever.
Jin C; Hill J; Gunn BM; Yu WH; Dahora LC; Jones E; Johnson M; Gibani MM; Spreng RL; Alam SM; Nebykova A; Juel HB; Dennison SM; Seaton KE; Fallon JK; Tomaras GD; Alter G; Pollard AJ
J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33180929
[TBL] [Abstract][Full Text] [Related]
12. Vaccines for preventing typhoid fever.
Milligan R; Paul M; Richardson M; Neuberger A
Cochrane Database Syst Rev; 2018 May; 5(5):CD001261. PubMed ID: 29851031
[TBL] [Abstract][Full Text] [Related]
13. Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial.
Kantele A; Pakkanen SH; Karttunen R; Kantele JM
PLoS One; 2013; 8(4):e60583. PubMed ID: 23593253
[TBL] [Abstract][Full Text] [Related]
14. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
Ni Y; Springer MJ; Guo J; Finger-Baker I; Wilson JP; Cobb RR; Turner D; Tizard I
Vaccine; 2017 Dec; 35(51):7121-7126. PubMed ID: 29150208
[TBL] [Abstract][Full Text] [Related]
15. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?
Pulickal AS; Pollard AJ
Expert Rev Vaccines; 2007 Jun; 6(3):293-5. PubMed ID: 17542742
[No Abstract] [Full Text] [Related]
16. A Salmonella typhi Vi conjugate vaccine.
Koul PA
N Engl J Med; 2001 Aug; 345(7):545-6. PubMed ID: 11519517
[No Abstract] [Full Text] [Related]
17. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
[TBL] [Abstract][Full Text] [Related]
18. Vi Capsular Polysaccharide Produced by Recombinant
Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
